|Statement||edited by J. Reichen and R.E. Poupon.|
|Contributions||Reichen, J., Poupon, R. E.|
|LC Classifications||RC847 .F35 1995|
|The Physical Object|
|Pagination||xii, 213 p. :|
|Number of Pages||213|
|LC Control Number||96017380|
Disease status usually is monitored by physical assessment, ultrasound imaging of the liver, and analysis of serum for a panel of markers Many of the constituents of the serum panel (e.g., ALT levels) vary throughout the course of chronic hepatitis and are of limited use in early detection of by: 2. Falk Symposium: Surrogate Markers to Assess Efficacy of Treatment in Chronic Liver Diseases: Proceedings of the International Falk Workshop Held in Basel, Switzerland, October , 88b (1st Edition) by Editor-J. Reichen, Jürg Reichen, R. E. Poupon Hardcover, Pages, Published ISBN / ISBN / Book Edition: 1st Edition. 1. Author(s): Reichen,J(Jurg); Poupon,R E; International Falk Workshop,( Basel, Switzerland) Title(s): Surrogate markers to assess efficacy of treatment in chronic liver diseases: proceedings of the International Falk Workshop held in Basel, Switzerland, October , / edited by J. Reichen and R.E. Poupon. Surrogate markers to assess efficacy of treatment in chronic liver diseases. Cartea pe care o cauti este aici! Este aparuta in anul la Editura Wolters Kluwer. Intra si lanseaza o comanda de la anticariatul Printre Carti!
A combination of biomarkers measuring degradation and formation of specific ECM proteins may thus act as surrogate markers and assess the efficacy of therapy. from chronic liver diseases. According to section (e)(9) of the FD&C Act “[t]he term ‘surrogate endpoint’ means a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure, that is. Laurent Castera, Invasive and non-invasive methods for the assessment of fibrosis and disease progression in chronic liver disease, Best Practice & Research Clinical Gastroenterology, /, 25, 2, (), (). Currently, the only accepted method (gold standard) for the diagnosis of the fibrotic stages of chronic liver disease (CLD) is liver biopsy, to allow histological assessment. Liver biopsy is an invasive investigation associated with a range adverse events (e.g., pain and hemorrhage), 1, 2 limiting its serial usage in clinical practice.
Some biomarkers, most particularly the liver function tests GGT, ASAT, and ALAT, provide important information on health status, a goal of alcohol treatment in its own right. Finally, biomarker changes may also inform data–monitoring boards on the safety of an intervention, especially a . Current and emerging surrogate markers of hepatic fibrosis in primary biliary cirrhosis (PBC) is a chronic, nonsuppurative cholangitic liver disease, with progressive loss of interlobular and septal bile ducts. and compared serum tests with histological features of disease identified at baseline and 3 years following treatment. In terms. In contrast, pathologists' agreement over histologic scores ranged from very good to moderate (kappa). CONCLUSIONS: Assessment of liver fibrosis with multiple serum markers used in combination is sensitive, specific, and reproducible, suggesting they may be used in conjunction with liver biopsy to assess a range of chronic liver diseases. Non-alcoholic fatty liver disease (NAFLD) has become the most prevalent chronic liver disease in western countries. 1,2 It is closely associated with obesity, diabetes, dyslipidaemia and the metabolic syndrome, and shares common risk factors and pathophysiological mechanisms with these entities. 2,3 NAFLD can be associated with hepatocellular damage and inflammation and is then .